Core Viewpoint - Recently, the company reported a decline in revenue and incurred losses for the first three quarters of 2025, indicating challenges in its financial performance [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 581 million, a year-on-year decrease of 4.1% [1] - The net profit attributable to the parent company was a loss of 45.92 million [1] - In the third quarter, the operating revenue was 204 million, reflecting a year-on-year decline of 8.9% [1] - The net profit attributable to the parent company for the third quarter was a loss of 14.54 million [1] Regulatory Approvals - During the reporting period, the company received approval from the National Medical Products Administration for the injection of Mycophenolate Mofetil (specification: 0.5g) and obtained drug registration certificates for Nicorandil tablets (specification: 5mg) and Ketorolac Tromethamine injection (specification: 1ml: 30mg) [1] Shareholding Changes - On September 26, 2025, the company was notified by its controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as "Zhongheng Group"), about a capital increase agreement and share transfer agreement signed by its indirect controlling shareholder, Guangxi Investment Group Co., Ltd. (hereinafter referred to as "Guangxi Investment Group") [1] - Guangxi Investment Group plans to increase capital in Guangxi Investment Group Financial Holdings Co., Ltd. (hereinafter referred to as "Guangxi Financial Holdings") by transferring 859,343,587 shares of Zhongheng Group [1] - After the completion of this transaction, Guangxi Financial Holdings will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the Guangxi State-owned Assets Supervision and Administration Commission will continue to be the actual controller of the company [1]

尼可地尔片用于心绞痛的治疗。最早由日本中外制药有限公司开发，1983年在日本上市销售，2006年批 准进入中国市场，商品名为喜格迈（Sigmart）。 根据摩熵医药数据，2022年—2024年，尼可地尔片在 中国医院全终端市场销售额由6.76亿元攀升至8.73亿元，该产品的获批将有力补充公司心血管产品线， 提升市场覆盖能力。 酮咯酸氨丁三醇注射液适用于中度至重度急性术后疼痛的短期治疗。该药物由瑞士的罗氏（Roche）公 司研发，于1989年11月在美国上市。该药于2005年在中国获批上市，由山东新时代药业有限公司（鲁南 制药集团旗下）推出，用于成人术后中度至重度急性疼痛的短期治疗。根据摩熵医药数据，酮咯酸氨丁 三醇注射液2022年—2024年在中国医院（全终端）市场销售额分别为26.43亿元、18.92亿元、8.98亿 元。 莱美药业表示，未来，公司将持续聚焦优势细分领域，保持新品持续引进，加快对已引入新品的上市转 换，加大自主创新力度，积极迎接医药行业的机遇并应对挑战，推动公司健康持续发展。 （文章来源：证券时报网） 10月21日晚间，莱美药业(300006)发布三季报，前三季度，公司报告期实现营业收入5. ...